

CURRENT CLAIMS
(AS AMENDED FEBRUARY 20, 2001 WITH
SUPPLEMENTAL AMENDMENT AND INTERVIEW SUMMARY)

15. A method for treating a disorder resulting from platelet activation or adherence in an animal or human, comprising administering to the animal or human a composition comprising nitrosated or nitrated hemoglobin in a therapeutically effective amount.
16. The method of Claim 15 wherein the disorder is selected from the group consisting of: myocardial infarction, pulmonary thromboembolism, cerebral thromboembolism, thrombophlebitis, sepsis and unstable angina.
17. (Amended) A method for preventing thrombus formation in an animal or human, comprising administering to the animal or human a composition comprising nitrosated hemoglobin in a therapeutically effective amount.
59. A method for inhibiting platelet activation in a mammal, comprising administering to the mammal a composition comprising nitrosated hemoglobin in a therapeutically effective amount.
60. A method for treating a disorder resulting from platelet activation or adherence in an animal or human, comprising administering to the animal or human a composition comprising nitrosylhemoglobin in a therapeutically effective amount.
61. The method of Claim 60 wherein the disorder is selected from the group consisting of: myocardial infarction, pulmonary thromboembolism, cerebral thromboembolism, thrombophlebitis, sepsis and unstable angina.

62. A method for preventing thrombus formation in an animal or human, comprising administering to the animal or human a composition comprising nitrosylhemoglobin in a therapeutically effective amount.
63. A method for inhibiting platelet activation in a mammal, comprising administering to the mammal a composition comprising nitrosylhemoglobin in a therapeutically effective amount.
64. A method for treating a disorder resulting from platelet activation or adherence in an animal or human, comprising administering to the animal or human a composition comprising SNO-Hb[Fe(III)] in a therapeutically effective amount.
65. A method for preventing thrombus formation in an animal or human, comprising administering to the animal or human a composition comprising SNO-Hb[Fe(III)] in a therapeutically effective amount.
66. A method for treating a disorder resulting from platelet activation or adherence in an animal or human, comprising administering to the animal or human a composition comprising polynitrosated hemoglobin in a therapeutically effective amount.
67. A method for treating a disorder resulting from platelet activation or adherence in an animal or human, comprising administering to the animal or human a composition comprising SNO-Hb[Fe(II)] in a therapeutically effective amount.
68. A method for preventing thrombus formation in an animal or human, comprising administering to the animal or human a composition comprising polynitrosated hemoglobin in a therapeutically effective amount.

69. A method for preventing thrombus formation in an animal or human, comprising administering to the animal or human a composition comprising SNO-Hb[Fe(II)] in a therapeutically effective amount.
70. A method for inhibiting platelet activation in a mammal, comprising administering to the mammal a composition comprising SNO-hemoglobin in a therapeutically effective amount.
71. A method for inhibiting platelet activation in a mammal, comprising administering to the mammal a composition comprising SNO-methemoglobin in a therapeutically effective amount.